Propanc Biopharma, Inc. (PPCB)

OTCMKTS · Delayed Price · Currency is USD
3.000
-2.500 (-45.45%)
Apr 25, 2025, 1:57 PM EDT
142,757%
Market Cap 34.84M
Revenue (ttm) n/a
Net Income (ttm) -1.86M
Shares Out 11.61M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,316
Average Volume 1,119
Open 3.990
Previous Close 5.500
Day's Range 3.000 - 5.000
52-Week Range 0.000 - 145.460
Beta 17,240.95
RSI 43.54
Earnings Date May 15, 2025

About Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research collaboration with University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation; and a joint ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol PPCB
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.